Monthly Archives: September 2010

Don’t Be Afraid of “Frankenfish”

The Wall Street Journal ran on September 23, 2010, an op-ed authored by BIO President and CEO Jim Greenwood about FDA’s pending approval of a genetically engineered salmon.  This salmon can help meet the growing demand for protein-rich food without depleting wild fish stocks. Right now, the government is deciding whether it’s safe for us to eat genetically engineered salmon. The fish, called AquAdvantage, is being developed by a Massachusetts biotech firm and is in Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Science Advisory Board Has Rigorous Discussion on GE Salmon

FDA Approval Could Pave the Way for Future Science-based Technologies  As part of the U.S. Food and Drug Administration’s rigorous, scientific regulatory review governing genetically engineered (GE) animal technologies, the FDA’s Veterinary Medicine Advisory Committee (VMAC) hosted a rigorous discussion about a GE salmon on September 19-21.  The AquAdvantage® Salmon is genetically engineered to reach its market weight in half the time of conventionally raised salmon thus contributing to more sustainable aquaculture systems.  It was Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , ,

Icons: What Do They Mean?

We are pleased to announce the release of one of our newest software improvements to the BIO One-on-One Partnering System. I’m sure most of you have noticed the little gold medallions marking the names of several of the companies in the 1×1 system for the 2010 BIO Investor Forum. They denote those companies which are Presenters (P), BIO Members (B), BIO Board Members (M), and Conference Sponsor (S). We continue to look for ways to Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , ,

IPO update: 28 IPOs, 24 on Deck

The number of IPOs slowed during the summer, but the queue has been filling nicely.  Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

Therapeutic Discovery Program Is a Shot in the Arm for Small Biotechs

Innovation is one of the things Americans do best and when it comes to creating new therapies, it’s also a key to job growth, strong small businesses, and our industry’s ability to address the needs of patients suffering from debilitating diseases such as cancer, HIV/AIDS and Alzheimer’s. The recently implemented Therapeutic Discovery Project Program offers a tax credit to small biotechnology companies on the cusp of discovering cutting-edge treatments and technologies that will have a Read More >

Jim's Corner  |  Leave a comment  |  Email This Post